Importantly, like ESO in pregnancy, EPL has a good safety profile in younger women, with very low risk of hyperkalaemia, and no sex steroid receptor effects, unlike other MR antagonists such as spironolactone. This evidence concerns the gene NR3C2 and Hyperkalemia.